Jean-Marc SABATIER is a Director of research at the French CNRS, with PhD degree in Cell Biology & Microbiology, and HDR degree in Biochemistry. He headed several academic research teams (CNRS, INSERM and University), as well as a combined academic-industry research laboratory devoted to the engineering of therapeutic peptides (ERT62, Marseilles, France). He was also a Director of Research for several French private companies as well as a Canadian public company. Dr. Sabatier works in the field of animal toxins and microbes. He so far contributed to 36 special issues or books in toxinology and virology, and about 280 scientific articles, 201 communications, and 55 patents in both biology and chemistry. He acts as the Editor-in-Chief of the journals ‘Coronaviruses’, and ‘Journal of Current Toxicology and Venomics’. He is the Editor of E-Book series ‘Coronaviruses’. He is a member of 74 Editorial Boards of scientific journals (impact factors up to 11.4), such as ‘Journal of Advanced Research’ (Associate Editor), ‘Peptides’, ‘Molecules’, ‘Antibiotics’ (section Editor-in-Chief), and ‘Frontiers in Pharmacology’ (Associate Editor). He also reviewed articles submitted for publication in 112 international journals (impact factors up to 35) and acts as an expert for numerous national and international institutions. He won the ‘Citizen of the Year Award’ from the Nouvel Economiste (1994) for his work on antivirals. He is a member of a dozen scientific societies, such as the ‘American Peptide Society’ (charter member), ‘European Peptide Society’, ‘American Society for Microbiology’, ‘Biochemical Society’ and ‘New-York Academy of Sciences’.

• Drug Design
• Antimicrobials
• Venoms
• Microbial Toxins
• Animal Toxins
• Peptide and Protein Engineering
• Structure-activity

• Vitamin D and mitochondrial activity preservation in COVID-19. Giacomoni, J., Sabatier, J.-M., Infectious Disorders-Drug Targets, 25(1): e190424229153 (2025). Doi: 10.2174/0118715265304580240405064250
• Renin-angiotensin system dysregulation: ADAM17 activation consequences related to SARS-CoV-2. Giacomoni, J., Sabatier, J.-M., Infectious Disorders-Drug Targets, 25(1): e29042429522 (2025). Doi: 10.2174/0118715265299597240422102455
• SARS-CoV-2 or vaccinal spike protein can induce mast cell activation syndrome (MCAS). Fajloun, Z., Khattar, Z.A., Sabatier, J.-M., Infectious Disorders-Drug Targets, 25(1): e300424229561 (2025). Doi: 10.2174/0118715265319896240427045026
• Malignant tumors in vagal-innervated organs: exploring its homeostatic role. Martinez, P., Sabatier, J.-M., Cancer Lett., (2025). Doi: 10.1016/j.canlet.2025.217539
• Unveiling the role of SARS-CoV-2 or mRNA vaccine spike protein in macrophage activation syndrome (MAS). Fajloun, Z., Tajer, L., Khattar, Z.A., Sabatier, J.-M., Infectious Disorders-Drug Targets (2024). Doi: 10.2174/0118715265341206240722050403
• Rethinking corticosteroids use in Oncology. Martinez, P., Sabatier, J.-M., Frontiers in Pharmacology, in press (2025).
• The possible role of nuclear factor erythroid-2-related factor 2 activators in the management of Covid-19. Al-Kuraishy, H.M., Al-Gareeb, A.I., Eldahshan, O.A., Abdelkhalek, Y.M., Eldahshan, M., Ahmed, E.A., Sabatier, J.-M., El-Saber Bathila, G., Journal of Biochemical and Molecular Toxicology 38(1), e23605 (2024). Doi: 10.1002/jbt.23605
• The unsuspected role of the renin-angiotensin system (RAS): could its dysregulation be at the root of all non-genetic human diseases? Fajloun, Z., Sabatier, J.-M., Infectious Disorders-Drug Targets (2024). Doi: 10.2174/1871526524666230914524
• Treating COVID-19 with medicinal plants: is it even conceivable? A comprehensive review. Al-Jamal, H., Idriss, S., Roufayel, R., Abi Khattar, Z., Fajloun, Z., Sabatier, J.-M., Viruses, 16(3), 320 (2024). Doi: 10.3390/v16030320
• The intriguing connection between cholestasis and the renin-angiotensin system dysregulation induced by SARS-CoV-2 and/or the vaccinal spike protein. Fajloun, Z., Khattar, Z.A., Sabatier, J.-M., Infectious Disorders-Drug Targets (2024). Doi: 102174/0118715265304515240220105152
• Structural and functional venomics as a powerful approach for drug discovery and development. Abdel-Rahman, M.A., Cao, Z., Abd El-Aziz, Strong, P.N., Sabatier, J.-M., Frontiers in Pharmacology 15, 1405681 (2024). Doi: 10.3389/fphar.2024.1405681
• Neuroarchitecture: how the perception of our surroundings impacts the brain. Abbas, S., Okdeh, N., Roufayel, R., Kovacic, H., Sabatier, J.-M., Fajloun, Z., Abi Khattar, Z., Biology, 13(4), 220 (2024). Doi: 10.3390/biology13040220
• Unlocking the benefits of fasting: a review of its impact on various biological systems and human health. Mackieh, R., Al-Bakkar, N., Kfoury, M., Okdeh, N., Pietra, H., Roufayel, R., Legros, C., Fajloun, Z., Sabatier, J.-M., Current Medicinal Chemistry 31(14), 1781-1803 (2024). Doi: 10.2174/0109298673275492231121062033
• Molecular mechanisms of bacterial resistance to antimicrobial peptides in the modern era: an updated review. Tajer, L., Paillart, J.-C., Dib, H., Sabatier, J.-M., Fajloun, Z., Abi Khattar, Z., Microorganisms, 12(7), 1259 (2024). Doi: 10.3390/microorganisms12071259
• Structural and functional venomics as a powerful approach for drug discovery and development. Zhang, J., Sabatier, J.-M., Chahine, M., Tricarico, D., Frontiers in Pharmacology 15, 1449967 (2024). Doi: 10.3389/fphar.2024.1449967
• Effect of Apis mellifera syriaca bee venom on glioblastoma cancer: in vitro and in vivo studies. Chala, C., Rima, M., Mouawad, C., Roufayel, R., Kovacic, H., El Obeid, D., Sabatier, J.-M., Luis, J., Fajloun, Z., El-Waly, B., Molecules, 29, 3950 (2024). Doi: 10.3390/molecules29163950
• From endogenous quasi-pathogens to endogenous smart medicine: understanding the cellular mechanisms and implications of benign and malignant cell dynamics. Sabatier, J.-M., Amini, F., Biophysica, 4, 453-465 (2024). Doi: 10.3390/biophysica4030029
• The relationship between SARS-CoV-2, vaccine spike protein, renin-angiotensin system and epilepsy. Fajloun, Z., Tajer, L., Kovacic, H., Sabatier, J.-M., Infectious Disorders-Drug Targets (2024). Doi: 10.2174/0118715265350339240919053408.
• Plant metabolomics: the future of anticancer drug discovery. Dabbousy, R., Rima, M., Roufayel, R., Rahal, M., Legros, C., Sabatier, J.-M., Fajloun, Z., Pharmaceuticals 17(10), 1307-1333 (2024). Doi: 10.3390/ph17101307
• Lesser known cyanotoxins: a comprehensive review of their health and environmental impacts. Al Haffar, M., Fajloun, Z., Azar, S., Sabatier, J.-M., Abi Khattar, Z., Toxins, 16, 551 (2024). Doi : 10.3390/toxins16120551
• Phytochemical constituents, folk medicinal uses, and biological activities of genus Angelica: a review. El-Saber Bathila, G., Shaheen, H.M., Elhawary, E.A., Mostafa, N.M., Eldahshan, O.A., Sabatier, J.-M., Molecules, 28, 267 (2023). Doi: 10.3390/molecules28010267
• COVID-19 and Ehlers-Danlos syndrome: the dangers of the Spike protein of SARS-CoV-2. Fajloun, Z., Legros, C., Sabatier, J.-M., Infectious Disorders-Drug Targets, (2023). Doi: 10.2174/1871526523666230104145108
• Why can high-level athletes develop very severe or fatal forms after intense exercise following SARS-CoV-2 infection or anti-Covid vaccination? Fajloun, Z., Khattar, Z.A., Kovacic, H., Legros, C., Sabatier, J.-M., Infectious Disorders-Drug Targets, (2023). Doi: 10.2174/1871526523666230111104355
• Isolation and molecular characterization of Corynebacterium pseudotuberculosis: association with proinflammatory cytokines in caseous lymphadenitis pyogranulomas. Torky, H.A., Saad, H.M., Khaliel S.A., Kassih, A.T., Sabatier, J.-M., El-Saber Bathila, G., Hetta, H.F., Elghazaly, E.M., De Waard, M., Animals, 13(2), 296 (2023). Doi: 10.3390/ani13020296
• Emergence of gloomy eyelet inside DNA. Sabatier, J.-M., Amini, F., Biophysica, 3, 35-45 (2023). Doi: 10.3390/biophysica3010003
• Identifying the geographic distribution pattern of venomous reptiles and regions of high snakebite risk in Iran. Kazemi, S.M., Hosseinzadeh, M.S., Sabatier, J.-M., Animals (2023). In press.
• Protective role and functional engineering of neuropeptides in depression and anxiety: an overview. Okdeh, N., Mahfouz, G., Harb, J., Sabatier, J.-M., Roufayel, R., Hanna, E.G., Kovacic, H., Fajloun, Z., Bioengineering, 10(2), 258 (2023). Doi: 10.3390/bioengineering10020258
• Overexpression of a novel Noxo1 mutant increases Ros production and Noxo1 relocalisation. Benssouina, F.Z., Parat, F., Villard, C., Leloup, L., Garrouste, F., Sabatier, J.-M., Ferhat, L., Kovacic, H., Int. J. Mol. Sci., 24(5), 4663 (2023). Doi: 10.3390/ijms24054663
• SIBO: the trail of a new human pathology associated with multiple severe and disabling Covid-19 and long Covid symptoms or induced by the anti-Covid-19 vaccine. Fajloun, Z., Khattar, Z.A., Kovacic, H., Legros, C., Sabatier, J.-M., Infectious Disorders-Drug Targets, (2023). Doi: 10.2174/1871526523666230210162334
• Understanding and relieving of neuropathic disorders in the long Covid. Fajloun, Z., Khattar, Z.A., Kovacic, H., Legros, C., Sabatier, J.-M., Infectious Disorders-Drug Targets, (2023). Doi: 10.2174/1871526523666230227113205
• Anti-Covid-19 vaccination, Covid-19, and female contraception: the exacerbated risk (thromboembolism) of the estrogen-progestin pill. Fajloun, Z., Khattar, Z.A., Kovacic, H., Legros, C., Sabatier, J.-M., Infectious Disorders-Drug Targets, (2023). Doi: 10.2174/1871526523666230224094439
• Inhibitors of ATP synthase as new antibacterial candidates. Mackieh, R., Al-Bakkar, N., Kfoury, M., Roufayel, R., Sabatier, J.-M., Fajloun, Z., Antibiotics, 12, 650 (2023). Doi: 10.3390/antibiotics12040650
• Inhibition mechanism of methicillin-resistant Staphylococcus aureus by zinc oxide nanorods via suppresses penicillin-binding protein 2a. Hassan, A., Al-Salmi, F.A., Saleh, M.A., Sabatier, J.-M., Alatawi, F.A., Alenezi, M.A., Albalwe, F.M., Albalawi, H.M., Darwish, D.B., Sharaf, E.M., ACS Omega, 8(11), 9969-9977 (2023). Doi: 10.1021/acsomega.2c07142
• Oxidative stress-induced hormonal disruption in male reproductive organ. Rotimi, D., Acho, M.A., Falana, B.M., Olaolu, T.D., Mgbojikwe, I., Althumairy, D., El-Saber Bathila, G., Adeyemi, O., Sabatier, J.-M., De Waard, M., Frontiers in Endocrinology, in press (2023).
• Long COVID and risk of erectile dysfunction in recovered patients from mild to moderate COVID-19. Al-Kuraishy, H.M., Al-Gareeb, A.I., Alarfaj, S.J., Al-Akeel, R.K., Faidah, H., El-Bouseary, M.M., Sabatier, J.-M., De Waard, M., El-Masry, T.A., El-Saber Bathila, G., Scientific Reports, 13(1), 5977 (2023). Doi: 10.1038/s41598-023-32211-5
• COVID-19 and Alzheimer’s disease: the link finally established. Fajloun, Z., Wu, Y., Cao, Z., Kovacic, H., Sabatier, J.-M., Infectious Disorders-Drug Targets, (2023). Doi: 10.2174/1871526523666230529162633
• COVID-19 and Parkinson’s disease: the link also established! Fajloun, Z., Wu, Y., Cao, Z., Kovacic, H., Sabatier, J.-M., Infectious Disorders-Drug Targets, (2023). Doi: 10.2174/1871526523666230619104142
• COVID-19 and anti-Covid-19 vaccination: potential damages to the thyroid gland. Fajloun, Z., Abi Khattar, Z., Kovacic, H., Sabatier, J.-M., Infectious Disorders-Drug Targets, (2023). Doi: 10.2174/1871526523666230509112038
• Toxicity of SARS-CoV-2 Spike protein from the virus and produced from COVID-19 mRNA or adenoviral DNA vaccines. Lesgards, J.-F., Cerdan, D., Perronne, C., Sabatier, J.-M., Azalbert, X., Rodgers, E.A., McCullough, P.A., Archives of Microbiology and Immunology, 7(3), 121-138 (2023).
• The relationship between COVID-19 viral load and disease severity: a systematic review. Dadras, O., Afsahi, A.M., Pashaei, Z., Mojdeganlou, H., Karimi, A., Habibi, P., Barezegary, A., Fakhfouri, A., Mirzapour, P., Janfaza, N., Dehghani, S., Afroughi, F., Dashti, M., Khodaei, S., Mehraeen, E., Voltarelli, F., Mehrtak, M., Mohssenipour, M. Moradmand-Badie, B., Heydari, M., Sabatier, J.-M., Alinaghi, S.A., Immunity, Inflammation and Disease, 10(3):e580 (2022). Doi : 10.1002/iid3.580
• Impact of COVID-19 pandemic on routine vaccination coverage of children and adolescents: a systematic review. Alinaghi, S.A., Karimi, A., Mojdeganlou, H., Alilou, S., Mirghaderi, S.P., Noori, T., Shamsabadi, A., Dadras, O., Vahedi, F., Mohammadi, P., Shojaei, A., Mahdiabadi, S., Janfaza, N., Lonbar, A.K., Mehraeen, E., Sabatier, J.-M., Health Science Reports 5(2): e00516 (2022). Doi : 10.1002/hsr2.516
• Angiotensin II Type I receptor (AT1R): the gate towards COVID-19-associated diseases. El-Arif, G., Khazaal, S., Farhat, A., Harb, J., Annweiler, C., Wu, Y., Cao, Z., Kovacic, H., Abi Khattar, Z., Fajloun, Z., Sabatier, J.-M., Molecules, 27(7), 2048 (2022). Doi : 10.3390/molecules27072048
• Discovery of Leptulipin, a new anticancer protein from the Iranian scorpion, Hemiscorpius lepturus. Rezaei, A., Asgari, S., Komijani, S., Sadat, S.N., Sabatier, J.-M., Bagheri, K.P., Shahbazzadeh, D., Akbari Eidgahi, M.R., De Waard, M., Mirzahoseini, H., Molecules, 27(7), 2056 (2022). Doi : 10.3390/molecules27072056
• Parkinson disease: protective role and function of neuropeptides. Tabikh, M., Chahla, C., Okdeh, N., Kovacic, H., Sabatier, J.-M., Fajloun, Z., Peptides, 151 :170713 (2022). Doi : 10.1016/j.peptides.2021.170713
• SARS-CoV-2-induced neurological disorders in symptomatic Covid-19 and long Covid patients: key role of brain renin-angiotensin system. Fajloun, Z., Kovacic, H., Annweiler, C., Wu, Y, Cao, Z., Sabatier, J.-M., Infectious Disorders-Drug Targets, 22(5), 3-5 (2022). Doi: 10.2174/1871526522666220406124618.
• The pathophysiology of long COVID throughout the renin-angiotensin system. Khazaal, S., Harb, J., Rima, M., Annweiler, C., Wu, Y., Cao, Z., Abi Khattar, Z., Legros, C., Kovacic, H., Fajloun, Z., Sabatier, J.-M., Molecules, 27(9), 2903 (2022). Doi : 10.3390/molecules27092903
• Current treatments and therapeutic options for COVID-19 patients: a systematic review. Mehraeen, E., Najafi, Z., Hayati, B., Javaherian, M., Rahimi, S., Dadras, O., Alinaghi, S.A., Ghadimi, M., Sabatier, J.-M., Infectious Disorders-Drug Targets, 22(1):e260721194968 (2022). Doi: 10.2174/187152652166621072650435
• DAMPening severe Covid-19 with Dexamethasone. Annweiler, C., Papon, N., Sabatier, J.M., Barré, J. Infectious Disorders-Drug Targets, 22(2):e270821195910, (2022). Doi: 10.2174/1871526521999210827142839
• Vaccines for COVID-19: a review of feasibility and effectiveness. Mehraeen, E., Dadras, O., Afsahi, A.M., Karimi, A., Mohssenipour, M., Mirzapour, P., Barzegari, A., Behnezhad, F., Habibi, P., Salehi, M.A., Vahedi, F., Heydari, M., Kianzad, S., Moradmand-Badie, B., Javaherian, M., SeyedAlinaghi, S., Sabatier, J.M. Infectious Disorders-Drug Targets, 22(2):e230921196758, (2022). Doi: 10.2174/1871526521666210923144837
• Shared food, meals and drinks: 10 arguments suggesting an oral transmission route of SARS-CoV-2. Wendling, J.-M., Saulnier, A., Sabatier, J.M., Infectious Disorders-Drug Targets, 22(2):e160721194830, (2022). Doi: 10.2174/1871526521666210716110603
• Counter-regulatory renin-angiotensin system: an important line of research to understand and limit the severity of COVID-19. Annweiler, C., Cao, Z., Papon, N., Kovacic, H., Sabatier, J.M. Infectious Disorders-Drug Targets, 22(2):e100921196331, (2022). Doi: 10.2174/1871526521666210910063227
• Neuro- and cardiovascular activities of Montivipera bornmuelleri snake venom. Sahyoun, C., Krezel, W., Mattei, C., Sabatier, J.-M., Legros, C., Fajloun, Z., Rima, M., Biology, 11(6), 888 (2022). Doi : 10.3390/biology11060888
• Structural dynamics of the SARS-CoV-2 spike protein: a 2-year retrospective analysis of SARS-CoV-2 variants (from alpha to omicron) reveals an early divergence between conserved and variable epitopes. Guérin, P., Yahi, N., Azzaz, F., Chahinian, H., Sabatier, J.-M., Fantini, J., Molecules, 27(12), 3851 (2022). Doi : 10.3390/molecules27123851
• Fast killing kinetics, significant therapeutic index, and high stability of melittin-derived antimicrobial peptide. Akbari, R., Hakemi-Vala, M., Sabatier, J.-M., Pooshang-Bagheri, K., Amino acids, 54(9), 1275-1285 (2022). Doi : 10.1007/s00726-022-03180-2
• Editorial: Venoms, animal and microbial toxins, Volume II. Cao, Z., Shahbazzadeh, D., Kovacic, H., McNutt, P.M., Wang, J.-L., Wulff, H., Utkin, Y.N., Sabatier, J.-M., Frontiers in Pharmacology, 13:973628 (2022). Doi: 10.3389/fphar.2022.973628
• Separation and analytical techniques used in snake venomics: a review article. Sahyoun, C., Rima, M., Mattei, C., Sabatier, J.-M., Fajloun, Z., Legros, C., Processes, 10(7), 1380 (2022). Doi : 10.3390/pr10071380
• SARS-CoV-2, Covid-19, and reproduction: effects on fertility, pregnancy, and neonatal life. Harb, J., Debs, N., Rima, M., Wu, Y., Cao, Z., Kovacic, H., Fajloun, Z., Sabatier, J.-M., Biomedicines, 10(8), 1775 (2022). Doi : 10.3390/biomedicines10081775
• Rhus coraria L. (Sumac), a versatile and resourceful food spice with cornucopia of polyphenols. El-Saber Batiha, G.E., Ogunyemi, O.M., Shaheen, H.M., Kutu, F.R., Olaiya, C.O., Sabatier, J.-M., De Waard, M., Molecules, 27(16), 5179 (2022). Doi : 10.3390/molecules27165179
• Role of Neuropilin 1 in COVID-19 patients with acute ischemic stroke. Al-Thomali, A.W., Al-Kuraishy, H.M., Al-Gareeb, A.I., Al-Buhadiliy, A.K., De Waard, M., Sabatier, J.-M., Khalil, A.A.K., Saad, H.M., El-Saber Bathila, G., Biomedicines, 10(8), 2032 (2022). Doi : 10.3390/biomedicines10082032
• The detection of potential native probiotics Lactobacillus spp. Against Salmonella Kentucky ST198 of Lebanese chicken origin. El Hage, R., El Hage, J., Snini, S.P. Ammoun, I., Touma, J., Rachid, R. Mathieu, F., Sabatier, J.-M., Abi Khattar, Z., El Rayess, Y., Antibiotics, 11(9), 1147 (2022). Doi: 10.3390/antibiotics11091147
• The potential role of Growth Differentiation Factor 15 in COVID-19: a corollary subjective effect or not?. Babalghith, A.O., Al-Kuraishy, H.M., Al-Gareeb, A.I., De Waard, M., Sabatier, J.-M., Saad, H.M., El-Saber Bathila, G., Diagnostics, 12(9), 2051 (2022). Doi : 10.3390/diagnostics12092051
• Roxadustat for SARS-CoV-2 infection: old signaling raised new hopes. Alkazmi, L., Al-Kuraishy, H.M., El-Saber Bathila, G., Mostafa-Hedeab, G., De Waard, M., Sabatier, J.-M., Kabrah, S.M., Saad, H.M., Al-Gareeb, A.I., Simal-Gandara, J., Drugs in R&D, 22(3), 183-186 (2022). Doi : 10.1007/s40268-022-00397-0
• Covid-19 in pediatrics: the current knowledge and practice. Mehraeen, E., Oliaei, S., SeyedAlinaghi, S., Karimi, A., Mirzapour, P., Afsahi, A.M., Barzegari, A., Vahedi, F., Soleymanzadeh, M., Behnezhad, F., Javaherian, M., Zargari, G., Mirghaderi, S.P., Noori, T., Sabatier, J.M., Infectious Disorders-Drug Targets, 22(5), 47-57 (2022). Doi: 10.2174/1871526521666210929121705
• Montelukast and acute coronary syndrome: the endowed drug. Alomair, B.M., Al-Kuraishy, H.M., Al-Gareeb, A.I., Al-Hamash, S.M., De Waard, M., Sabatier, J.-M., Saad, H.M., El-Saber Bathila, G., Pharmaceuticals, 15(9), 1147 (2022). Doi: 10.3390/ph15091147
• Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Alsubaie, N., Al-Kuraishy, H.M., Al-Gareeb, A.I., Alharbi, B., De Waard, M., Sabatier, J.-M., Saad, H.M., El-Saber Bathila, G., Brain Sciences, 12(10), 1290 (2022). Doi: 10.3390/brainsci12101290
• Optimized chemical extraction methods of antimicrobial peptides from roots and leaves of extremophilic plants: Anthyllis sericea and Astragalus armatus collected from the Tunisian desert. Ben Brahim, R., Ellouzi, H., Fouzai, K., Asses, N., Neffati, M., Sabatier, J.-M., Bulet, P., Regaya, I., Antibiotics, 11(10), 1302 (2022). Doi: 10.3390/antibiotics11101302
• The role of Berberine in Covid-19: potential adjunct therapy. Babalghith, A.O., Al-Kuraishy, H.M., Al-Gareeb, A.I., De Waard, M., Al-Hamash, S.M., Sabatier, J.-M., Negm, W.A., El-Saber Bathila, G., Inflammopharmacology, (2022). Doi: 10.1007/s10787-022-01080-1
• The Lebanese red algae Jania rubens: promising biomolecules against colon cancer cells. Rifi, M., Radwan, Z., Al-Monla, R., Fajloun, Z., Sabatier, J.-M., Kouzayha, A., El-Sabban, M., Mawlawi, H., Dassouki, Z., Molecules, 27, 6617 (2022). Doi : 10.3390/molecules27196617
• Discovery of putative inhibitors against main drivers of SARS-CoV-2 infection: insight from quantum mechanical evaluation and molecular modeling. Balogun, T.A., Chukwudozie, O.S., Ogbodo, U.C., Junaid, I.O., Sunday, O.A., Ige, O.M., Aborode, A.T., Akintayo, A.D., Oluwarotimi, E.A., Oluwafemi, I.O., Saibu, O.A., Chuckwuemaka, P., Omoboyowa, D.A., Alausa, A.O., Atasie, N.H., Ilesanmi, A., Dairo, G., Tiamiyu, Z.A., Bathila, G.E., Alkhuriji, A.F., Al-Megrin, W.A.I., De Waard, M., Sabatier, J.-M., Frontiers in Chemistry, 10, 964446 (2022). Doi : 10.3389/fchem.2022.964446
• Phytochemical analysis and understanding the antioxidant and anticancer properties of methanol extract from Litsea Glutinosa: in vitro and in vivo studies. Shafiq, S., Zahan, R., Yesmin, S., Khan, A., Mahmud, M.S., Reza, M.A., Albogami, S.A., Alorabi, M., De Waard, M., Saad, H.M., Sabatier, J.-M., Naz, T., El-Saber Batiha, G.E., Molecules, 27, 6964 (2022). Doi : 10.3390/molecules27206964
• Purification and characterization of Bot33: a non-toxic peptide from the venom of Buthus occitanus tunetanus scorpion. ElFessi, R., Khamessi, O., Srairi-Abid, N., Sabatier, J.-M., Tytgat, J., Peigneur, S., Kharrat, R., Molecules, 27, 7278 (2022). Doi : 10.3390/molecules27217278
• Potential therapeutic benefits of Metformin alone and in combination with Sitagliptin in the management of type 2 diabetes patients with COVID-19. Al-Kuraishy, H.M., Al-Gareeb, A.I., Albogami, S.M., Sabatier, J.-M., Nadwa, E.H., Hafiz, A.A., Negm, W.A., Kamal, M., Al-Jouboury, M., Elekhnawy, E., El-Saber Bathila, G., De Waard, M., Pharmaceuticals, 15, 1361 (2022). Doi: 10.3390/ph15111361
• Hypoxia-Inducible Factor 1 and preeclampsia: a new perspective. Albogami, S.M., Al-Kuraishy, H.M., Al-Maiahy, T.J., Al-Buhadily, A.K., Al-Gareeb, A.I., Alorabi, M., Alotaibi, S.S., De Waard, M., Sabatier, J.-M., Saad, H.M., El-Saber Bathila, G., Current Hypertension Reports (2022). Doi: 10.1007/s11906-022-01225-1
• The potential role of MUC16 (CA125) biomarker in lung cancer: a magic biomarker but with adversity. Saad, H.M., Tourky, G.F., Al-Kuraishy, H.M., Al-Gareeb, A.I., Khattab, A.M., Elmasry, S.A., Alsayegh, A.A., Hakami, Z.H., Alsulimani, A., Sabatier, J.-M., Eid, M.W., Shaheen, H.M., Mohammed, A.A., El-Saber Bathila, G., De Waard, M., Diagnostics, 12(12), 2985 (2022). Doi: 10.3390/diagnostics12122985
• Prevalence, morpho-histopathological identification, clinical picture, and the role of Lernanthropus kroyeri to alleviate the zinc toxicity in Moron labrax. Abou Zaid, A.A., Abd El Maged, R.R., Rasheed, N., Mansour, D.M., Mahboub, H.H., Abd El-Lateef, H.M., Sabatier, J.-M., Saad, H.M., El-Saber Bathila, G., De Waard, M., Pathogens, 12(1), 52 (2023). Doi: 10.3390/pathogens12010052
• Mass spectrometry-based top-down and bottom-up approaches for proteomic analysis of the Moroccan Buthus occitanus scorpion venom. Daoudi, K., Malosse, C., Lafnoune, A., Darkaoui, B., Chakir, S., Sabatier, J.-M., Chamot-Rooke, J., Cadi, R., Oukkache, N., FEBS Open Bio. (2021). Doi : 10.1002/2211-5463.13143
• The cytotoxic effect of Apis mellifera venom with a synergistic potential of its two main components -Melittin and PLA2- on colon cancer HCT116 cell lines. Yaacoub, C., Rifi, M., El-Obeid, D., Mawlawi, H., Sabatier, J.-M., Coutard, B., Fajloun, Z., Molecules 26, 2264 (2021). Doi : 10.3390/molecules26082264
• Fecal metabolic profiling of breast cancer patients during neoadjuvant chemotherapy reveals potential biomarkers. Zidi, O., Souai, N., Raies, H., Ben Ayed, F., Mezlini, A., Mezrioui, S., Tranchida, F., Sabatier, J.-M., Mosbah, A., Cherif, A., Shintu, L., Kouidhi, S., Molecules 26, 2266 (2021). Doi : 10.3390/molecules26082266
• Snake venom components: tools and cures to target cardiovascular diseases. Frangieh, J., Rima, M., Fajloun, Z., Henrion, D., Sabatier, J.-M., Legros, C., Mattei, C., Molecules 26(8), 2223 (2021). Doi : 10.3390/molecules26082223
• Discovery of a new analgesic peptide, Leptucin, from the Iranian scorpion, Hemiscorpius lepturus. Bagheri-Ziari, S., Shahbazzadeh, D., Sardari, S., Sabatier, J.-M., Pooshang-Bagheri, K., Molecules 26, 2580 (2021). Doi: 10.3390/molecules26092580
• Nigella and honey: an efficient treatment against Covid-19? Wendling, J.-M., Sabatier, J.-M., Kopferschmitt, J., Hegel 2021/1 (N°1), 51-56 (2021). Doi: 10.3917/heg.111.0051
• Editorial: Venoms, animal and microbial toxins. Cao, Z., Wang, J.-L., McNutt, P.M., Utkin, Y.N., Shahbazzadeh, D., Wulff, H., Kovacic, H., Sabatier, J.-M., Frontiers in Pharmacology (2021). Doi: 10.3389/fphar.2021.706573
• Dairy-derived and egg white proteins in enhancing immune system against COVID-19. Batiha, G.E., Awad, D.A., Algammal, A.M., Nyamota, R., Wahed, M.I., Shah, M.A., Amin, M.N., Adetuyi, B.O, Hetta, H.H., Cruz-Martins, N., Koirala, N., Ghosh, A., Sabatier, J.-M., Frontiers in Nutrition (2021). Doi : 10.3389/fnut.2021.629440
• Beehive products as antibacterial agents: a review. Nader R.A., Mackieh, R., Wehbe, R., El Obeid, D., Sabatier, J.M., Fajloun, Z., Antibiotics 10, 717-741 (2021). Doi: 10.3390/antibiotics10060717
• Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19. Sun, F., Mu, C., Kwok, H.F., Xu, J., Wu, Y., Liu, W., Sabatier, J.M., Annweiler, C., Li, X., Cao, Z., Xie, Y., International Journal of Biological Sciences 17(9), 2348-2355 (2021). Doi: 10.7150/ijbs.57810
• Covid-19: is the oral transmission route during shared meals and drinks credible? Wendling, J.M., Saulnier, A., Sabatier, J.M., Virologie 25(4), 213-223 (2021). Doi: 10.1684/vir.2021.0910
• Montivipera bornmuelleri venom: inhibitory effect on Staphylococcus epidermidis and Escherichia coli F1F0-ATPases and cytotoxicity on HCT116 cancer cell lines. Kfoury, M., Mouawad, C., Rifi, M., Sadek, R., Sabatier, J.M., Nehme, H., Fajloun, Z., Sci. 3, 31 (2021). Doi: 10.3390/sci3030031
• Current treatments and therapeutic options for Covid-19 patients: a systematic review. Mehraeen, E., Najafi, Z., Hayati, B., Javaherian, M., Rahimi, S., Dadras, O., Alinaghi, S.A., Ghadimi, M., Sabatier, J.M., Infectious Disorders-Drug Targets, 21, (2021). Doi: 10.2174/1871526521666210726150435
• Genetic susceptibility of Covid-19: a systematic review of current evidence. Alinaghi, S.A., Mehrtak, M., Mohssenipour, M. Mirzapour, P., Barezegary, A., Habibi, P., Moradmand-Badie, B., Afsahi, A.M., Karimi, A., Heydari, M., Mehraeen, E., Dadras, O., Sabatier, J.M., Voltarelli, F., Eur. J. Med. Res., 26(1), 46 (2021). Doi: 10.1186/s40001-021-00516-8
• Antimicrobial peptides: a potent alternative to antibiotics. Rima, M., Rima, M., Fajloun, Z., Sabatier, J.M., Bechinger, B., Naas, T., Antibiotics 10, 1095 (2021). Doi: 10.3390/antibiotics10091095
• First detection of tobacco mosaic virus in tobacco fields in northern Lebanon. Obeid, R., Wehbe, E., Rima, M., Kabara, M., Al Bersaoui, R., Sabatier, J.M., Fajloun, Z., Gereige, D. Infectious Disorders-Drug Targets, 21, 534-540 (2021). Doi: 10.2174/1871526520666200928164057
• Voltage-gated sodium channels: a prominent target of marine drugs. Mackieh, R., Abou-Nader, R., Wehbe, R., Mattei, C., Legros, C., Fajloun, Z., Sabatier, J.M., Marine Drugs, 19(10), 562 (2021). Doi: 10.3390/md19100562
• The renin-angiotensin system: a key role in SARS-CoV-2-induced COVID-19. El-Arif, G., Farhat, A., Khazaal, S., Annweiler, C., Kovacic, H., Wu, Y., Cao, Z., Fajloun, Z., Abi Khattar, Z., Sabatier, J.M., Molecules, 26, 6945 (2021). Doi: 10.3390/molecules26226945
• Comparison of SARS-CoV-2 (Coronavirus) with other similar viruses based on current evidence. Kianzad, S., SeyedAlinaghi, S., Asadollahi-Amin, A., Dadras, O., Karimi, A., Afsahi, A.M., MohsseniPour, M., Barzegary, A., Pirzapour, P., Mirghaderi, S.P., Salehi, M.A., Pashaei, Z., Nazeri, Z., Behnezhad, F., Ali, Z., Noori, T., Mehraeen, E., Sabatier, J.-M., Jahanfar, S., Journal of Iranian Medical Council, 5(1), 4-26 (2021). Doi : 10.18502/jimc.v5i1.9565
• Topology, antiviral functional residues and mechanism of IFITM1. Sun, F., Xia, Z., Han, Y., Minjun, G., Wang, L., Wu, Y., Sabatier, J.-M., Miao, L., Cao, Z., Viruses, 12 (3), 295-308 (2020).
• Antibacterial peptides. Sabatier, J.-M., Antibiotics, 9 (4), 142 (2020).
• Novel mutant phospholipase D from Hemiscorpius lepturus acts as a highly immunogen in BALB/c mice against the lethality of scorpion venom. Soleimani Moez, A., Sajedi, R., Pooshang-Bagheri, K., Sabatier, J.-M., Shahbazzadeh, D., Molecules, 25 (7), 1673-1692 (2020).
• SARS-CoV-2 & Covid-19: Key-roles of the renin-angiotensin system / Vitamin D impacting drug and vaccine developments. Cao, Z., Wu, Y., Faucon, E., Sabatier, J.M., Infectious Disorders-Drug Targets, 20, 348-349 (2020). Doi: 10.2174/1871526520999200505174704
• Counter-regulatory ‘renin-angiotensin’ system-based candidate drugs to treat COVID-19 diseases in SARS-CoV-2-infected patients. Annweiler, C., Cao, Z., Wu, Y., Faucon, E., Mouhat, S., Kovacic, H., Sabatier, J.M., Infectious Disorders-Drug Targets, 20, 407-408 (2020). Doi: 10.2174/1871526520666200518073329
• Isolation, characterization and chemical synthesis of large spectrum antimicrobial cyclic dipeptide (L-leu-L-pro) from Streptomyces misionensis V16R3Y1 bacteria extracts. A novel 1H-NMR metabolomic approach. Saadouli, I., Zendah El Euch, I., Trabelsi, E., Mosbah, A., Redissi, A., Ferjani, R., Fhoula, I., Cherif, A., Sabatier, J.M., Sewald, N., Ouzari, H.I., Antibiotics, 9(5), 270-282 (2020).
• Antimicrobials from venomous animals: an overview. Yacoub, T., Rima, M., Karam, M., Sabatier, J.M., Fajloun, Z., Molecules, 25, 2402-2422 (2020).
• A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis. Karami, E., Sabatier, J.-M., Behdani, M., Irani, S., Kazemi-Lomedasht, F., J. Enzyme Inhib. Med. Chem., 35(1), 1233-1239 (2020).
• Neurological, cognitive and behavioral disorders during COVID-19: the nitric oxide track. Annweiler, C., Bourgeais, A., Faucon, E., Cao, Z., Wu, Y., Sabatier, J.M., Journal of American Geriatrics Society, 10.1111/jgs.166671 (2020). Doi: 10.1111/jgs.166671
• Point of view: Should COVID-19 patients be supplemented with vitamin D? Annweiler, C., Cao, Z., Sabatier, J.M., Maturitas, 140, 24-26 (2020). Doi: https://doi.org/10.1016/j.maturitas.2020.06.003
• Point Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-7. Gütschow, M., Eynde, J.J.V., Jampilek, J., Kang, C., Mangoni, A.A., Fossa, P., Karaman, R., Trabocchi, A., Scott, P.J.H., Reynisson, J., Rapposelli, S., Galdiero, S., Winum, J.Y., Brullo, C., Prokai-Tatrai, K., Sharma, A.K., Schapira, M., Azuma, Y.T., Cerchia, L., Spetea, M., Torri, G., Collina, S., Geronikaki, A., García-Sosa, A.T., Vasconcelos, M.H., Sousa, M.E., Kosalec, I., Tuccinardi, T., Duarte, I.F., Salvador, J.A.R., Bertinaria, M., Pellecchia, M., Amato, J., Rastelli, G., Gomes, P.A.C., Guedes, R.C., Sabatier, J.M., Estévez-Braun, A., Pagano, B., Mangani, S., Ragno, R., Kokotos, G., Brindisi, M., González, F.V., Borges, F., Miloso, M., Rautio, J., Muñoz-Torrero, D., Molecules, 25(13):2968 (2020). Doi: 10.3390/molecules25132968.
• Montelukast drug may improve COVID-19 prognosis: a review of evidence. Barré, J., Sabatier, J.M., Annweiler, C. Frontiers in Pharmacology, 11:1344 (2020). Doi: 10.3389/fphar.2020.01344.
• Vitamin D and survival in COVID-19 patients. A quasi-experimental study. Annweiler, C., Hanotte, B., de l’Eprevier, C.G., Sabatier, J.M., Lafaie, L., Célarier, T., J. Steroid Biochem. Mol. Biol. 204, 105771 (2020). Doi: 10.1016/j.jsbmb.2020.105771.
• Potential inhibitory effect of Apis mellifera’s venom and of its two main components -Melittin and PLA2- on Escherichia coli F1F0-ATPase. Nehme, H., Ayde, H., El Obeid, D., Sabatier, J.M., Fajloun, Z., Antibiotics 9(11):E824. (2020). Doi: 10.3390/antibiotics9110824.
• Reinfection risk of novel coronavirus (COVID-19): a systematic review of current evidence. SeyedAlinaghi, S.A., Oliaei, S., Kianzad, S., Alsahi, A.M., Mohssenipour, M., Barzegary, A., Mirzapour, P., Behnezhad, F., Noori, T., Mehraeen, E., Dadras, O., Voltarelli, F., Sabatier, J.M., World J. Virol. 9(5): 79-90 (2020). Doi: 10.5501/wjv.v9.i5.79.
• Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-4. Mangoni, AA., Guillou, C., Vanden Eynde, J.J., Hulme, C., Jampilek, J., Li, W., Prokai-Tatrai, K., Rautio, J., Collina, S., Tuccinardi, T., de Sousa, M.E., Sabatier, J.-M., Galdiero, S., Karaman, R., Kokotos, G., Torri, G., Luque, F.J., Vasconcelos, M.H., Hadjipavlou-Litina, D., Siciliano, C., Gütschow, M., Ragno, R., Gomez, P.A.C., Agrofoglio, L.A., Munoz-Torrero, D., Molecules, 24, 130-142 (2019).
• Review: Therapeutic potential of carbonic anhydrase inhibitors. Rahman, S., Bibi, S., Javed, T., Alam, F., Ali, A., Qureshi, Z.R., Ali, S., Ullah, M., Asad, M.H.B., Hasan, S.M.F., Sabatier, J.-M., Rizvanov, A.A., Pak. J. Pharm. Sci., 32, 709-720 (2019).
• Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-5. Mangoni, AA., Vanden Eynde J.J.,, Jampilek, J., Hadjipavlou-Litina, D., Liu, H., Reynisson, J., de Sousa, M.E., Gomez, P.A.C., Prokai-Tatrai, K., Tuccinardi, T., Sabatier, J.-M., Luque, F.J., Rautio, J., Karaman, R., Vasconcelos, M.H., Gemma, S., Galdiero, S., Hulme, C., Collina, S., Gütschow, M., Kokotos, G., Siciliano, C., Capasso, R., Agrofoglio, L.A., Ragno, R., Munoz-Torrero, D., Molecules, 24, 2415-2428 (2019).
• Proteomics study of southern Punjab Pakistani cobra (Naja naja: formerly Naja naja karachiensis) venom. Bin Asad, M.H., McCleary, R., Salafutdinov, I., Alam, F., Shah, H.S., Bibi, S., Ali, A., Khalid, S., Hasan, S.M.F., Sabatier, J.-M., De Waard, M., Hussian, I., Rizvanov, A.A., Toxicology & Environmental Chemistry, 101, 91-116 (2019).
• Venoms of Iranian Scorpions (Arachnida, Scorpiones) and their potential for drug discovery. Kazemi, S.M., Sabatier, J.-M., Molecules, 24, 2670-2690 (2019).
• Bee venom: overview of main compounds and bioactivities for therapeutic interests. Wehbe, R., Frangieh, J., El Obeid, D., Sabatier, J.-M., Fajloun, Z., Molecules, 24, 2997-3009 (2019).
• Development of a human scFv antibody targeting the lethal Iranian cobra (Naja oxiana) snake venom. Kazemi-Lomedasht, F., Yamabhai, M., Sabatier, J.-M., Behdani, M., Reza, M., Shahbazzadeh, D., Toxicon, 171, 78-85 (2019).
• Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-6. Vanden Eynde, J.J., Mangoni, A.A., Rautio, J., Leprince, J., Azuma, Y.T., García-Sosa, A.T., Hulme, C., Jampilek, J., Karaman, R., Li, W., Gomes, P.A.C., Hadjipavlou-Litina, D., Capasso, R., Geronikaki, A., Cerchia, .L, Sabatier, J.-M., Ragno, R., Tuccinardi, T., Trabocchi, A., Winum, J.Y., Luque, F.J., Prokai-Tatrai, K., Spetea, M., Gütschow, M., Kosalec, I., Guillou, C., Vasconcelos, M.H., Kokotos, G., Rastelli, G., de Sousa, M.E., Manera, C., Gemma, S., Mangani, S., Siciliano, C, . Galdiero, S., Liu, H., Scott, P.J.H., de Los Ríos, C., Agrofoglio, L.A., Collina, S., Guedes, R.C., Munoz-Torrero, D., Molecules, 25, 119-143 (2019).
• Action mechanism of melittin-derived antimicrobial peptides, MDP1 and MDP2, de novo designed against multidrug-resistant bacteria. Akbari, R., Hakemi-Vala, M., Hashemi, A., Aghazadeh, H., Sabatier, J.-M., Bagheri, K.P. Amino acids, 50, 1231-1243 (2018).
• Lethal toxic dose (i.p. LD50), total protein contents and comparative hemolytic potential of (99mTc-labeled & non-labeled) Naja naja karachiensis venom. Bin Asad, M.H., Asad, A.F., Bibi, S., Ullah, K., Javed, T., Ullah, M., Ali, A., Qureshi, Z.R., Amirzada, M.I., Al-Kahraman, Y.M., Hasan, S.M.F., Sabatier, J.-M., Rizvanov, A. Pak. J. Pharm. Sci., 31, 685-689 (2018).
• Membrane-active peptide PV3 efficiently eradicates multidrug-resistant Pseudomonas aeruginosa in a mouse model of burn infection. Memariani, H., Shahbazzadeh, D., Sabatier, J.-M., Pooshang Bagheri, K. APMIS, 126, 114-122 (2018).
• Vipers of the middle east: a rich source of bioactive molecules. Rima, M., Alavi-Naini, S.M., Karam, M., Sadek, R., Sabatier, J.-M., Fajloun, Z. Molecules, 23, 2721-2737 (2018).
• Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-3. Mangoni, AA., Tuccinardi, T., Collina, S., Vanden Eynde, J.J., Munoz-Torrero, D., Karaman, R., Siciliano, C., de Sousa, M.E., Prokai-Tatrai, K., Rautio, J., Guillou, C., Gütschow, M., Galdiero, S., Liu, H., Agrofoglio, L.A., Sabatier, J.-M., Hulme, C., Kokotos, G., You, Q., Gomez, P.A.C. Molecules, 23, 1596-1606 (2018).
• Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-2. Munoz-Torrero, D., Mangoni, A.A., Liu, H., Hulme, C., Rautio, J., Karaman, R., de Sousa, M.E., Prokai-Tatrai, K., Sabatier, J.-M., Siciliano, C., Luque, F.J., Kokotos, G., Ranio, R., Collina, S., Guillou, C., Gütschow, M., Agrofoglio, L.A. Molecules, 23, 65-74 (2017).
• Characteristics and lethality of a novel recombinant dermonecrotic venom phospholipase D from Hemiscorpius lepturus. Torabi, E., Behdani, M., Chafi, M.H., Moazzami, R., Sabatier, J.-M., Khalaj, V., Shahbazzadeh, D., Bagheri, K.P. Toxins, 9, 102-118 (2017).
• Treating autoimmune disorders with venom-derived peptides. Shen, B., Cao, Z., Li, W., Sabatier, J.-M., Wu, Y. Expert Opin. Biol. Ther., 17, 1065-1075 (2017).
• Preface. Sabatier, J.-M. Infect. Disorders Drug Targets, 17(1), 2 (2017).
• Special issue 'Structure-activity relationship of natural products'. Sabatier, J.-M. Molecules, 22(5) (2017).
• Consequences of Androctonus mauretanicus and Buthus occitanus scorpion venoms on electrolyte levels in rabbits. Daoudi, K., Chgoury, F., Rezzak, M., Bourouah, O., Boussadda, L., Soukri, A., Sabatier, J.-M., Oukkache, N. Heliyon, 3, 221-233 (2017).
• Peptide screen identifies a new NADPH oxidase inhibitor: impact on cell migration and invasion. Mousslim, M., Pagano, A., Andreotti, N., Garrouste, F., Thuault, S., Peyrot, V., Parat, F., Luis, J., Culcasi, M., Thétiot-Laurent, S., Pietri, S., Sabatier, J.-M., Kovacic, H., Eur. J. Pharmacol., 794, 162-172 (2017).
• Genetic characterization of lactic acid bacteria from Tunisian milk waste and their antimicrobial activity against some bacteria implicated in nosocomial infections. Ghodhbane, H., Alessandria, V., Snoussi, M., Elleuch, L., Trabelsi, I., Abdelly, C., Sabatier, J.-M., Cocolin, L., Regaya, I. Infect. Disord. Drug Targets, 16, 182-191 (2016).
• Mechanism of action and in vitro activity of short hybrid antimicrobial peptide PV3 against Pseudomonas aeruginosa. Memariani, H., Shahbazzadeh, D., Sabatier, J.-M., Memariani, M., Karbalaimahdi, A., Bagheri, K.P., Biochem. Biophys. Res. Commun., 479, 103-108 (2016).
• Editorial. Sabatier, J.-M. Infect. Disorders Drug Targets, 16(2), 78 (2016).
• Comparison of the neurotoxic and myotoxic effects of two Moroccan scorpion venoms and their neutralization by experimental polyclonal antivenom. Oukkache, N., Ahmad Rusmili, M.R., Othman, I., Ghalim, N., Chgoury, F., Boussadda, L., El Mdaghri, N., Sabatier, J.-M., Life Sciences, 124, 1-7 (2015).
• Correspondences between the binding characteristics of a non-natural peptide, Lei-Dab7, and the distribution of SK subunits in the rat central nervous system. Aidi-Knani, S., Pezard, L., Mpari, B., Ben Hamida, J., Sabatier, J.-M., Mourre, C., Regaya, I., Eur. J. Pharmacol., 752, 106-111 (2015).
• Endogenous animal toxin-like human beta-defensin 2 inhibits own K+ channels through interaction with channel extracellular pore region. Yang, W., Feng, J., Xiang, F., Xie, Z., Zhang, G., Sabatier, J.-M., Cao, Z., Li, W., Chen, Z., Wu, Y., Cell. Mol. Life Sci., 72, 845-853 (2015).
• Chlorotoxin: a helpful natural scorpion peptide to diagnose glioma and fight tumor invasion. Dardevet, L., Rani, D., Aziz, T., Bazin, I., Sabatier, J.-M., Fadl, M., Brambilla, E., De Waard, M., Toxins, 7, 1079-1101 (2015).
• Small-conductance Ca2+-activated potassium type 2 channels regulate the formation of contextual fear memory. Murthy, S.R., Sherrin, T., Jansen, C., Nijholt, I., Robles, M., Dolga, A.M., Andreotti, N., Sabatier, J.-M., Knaus, H.G., Penner, R., Todorovic, C., Blank, T., PLoS One, 10, e0127264 (2015).
• Characterization of Am IT, an anti-insect -toxin isolated from the venom of scorpion Androctonus mauretanicus. Oukkache, N., El Jaoudi, R., Chgoury, F., Rocha, M.T., Sabatier, J.-M., Acta Physiologica Sinica, 67, 295-304 (2015).
• Bacteriocins active against multi-resistant Gram-negative bacteria implicated in nosocomial infections. Ghodhbane, H., Elaidi, S., Sabatier, J.-M., Achour, S., Benhamida, J., Regaya, I., Infect. Disord. Drug Targets, 15, 2-12 (2015).
• Unusual binding mode of scorpion toxin BmKTX onto potassium channels relies on its distribution of acidic residues. Chen, Z., Hu, Y., Hu, J., Yang, W., Sabatier, J.-M., De Waard, M., Cao, Z., Li, X., Han, S., Wu, Y., Biochem. Biophys. Res. Comm., 447, 70-76 (2014).
• Protein content analysis and antimicrobial activity of the crude venom of Montivipera Bornmuelleri, a viper from Lebanon. Accary, C., Hraoui-Bloquet, S., Hamze, M., Mallem, Y., El Omar, F., Sabatier, J.-M., Desfontis, J.C., Fajloun, Z., Infect. Disord. Drug Targets, 14, 49-55 (2014).
• Evaluation of the lethal potency of scorpion and snake venoms and comparison between intraperitoneal and intravenous injection routes. Oukkache, N., El Jaoudi, R., Ghalim, N., Chgoury, F., Bouhaouala, B., El Mdaghri, N., Sabatier, J.-M., Toxins, 6, 1873-1881 (2014).
• Peptide binding to Ochratoxin A mycotoxin: a new approach in conception of biosensors. Bazin, I., Andreotti, N., Hassine, A.I., De Waard, M., Sabatier, J.-M., Gonzalez, C., Biosensors Bioelectronics, 40, 240-246 (2013).
• SKCa channels blockage increases the expression of Adenosine A2A receptor in Jurkat human T cells. Regaya, I., Aidi-Knani, S., By, Y., Condo, C., Gerolami, V., Berge-Lefranc, J.-L., Ben Hamide, J., Sabatier, J.-M., Fenouillet, E., Guieu, R., Ruf, J., Bioresearch Open Access, 2, 163-168 (2013).
• Cell penetration properties of a highly efficient mini Maurocalcine peptide. Tisseyre, C., Bahembera, E., Dardevet, L., Sabatier, J.-M., Ronjat, M., De Waard, M., Pharmaceuticals, 6, 320-339 (2013).
• Two conserved arginine residues from the SK3 channel outer vestibule control selectivity of recognition by scorpion toxins. Feng, J., Hu, Y., Yi, H., Yin, S., Han, S., Hu, J., Chen, Z., Yang, W., Cao, Z., De Waard, M., Sabatier, J.-M., Li, W., Wu, Y., J. Biol. Chem, 288, 12544-12553 (2013).
• The deciphered genome of Mesobuthus martensii uncovers the resistance mysteries of scorpion to its own venom and toxins at the ion channel level. Andreotti, N., Sabatier, J.-M., Toxins, 5, 2209-2211 (2013).
• Lacticin LC14, a new bacteriocin produced by Lactococcus lactis BMG6.14: isolation, purification and partial characterization. Lasta, S., Ouzari, H., Andreotti, N., Fajloun, Z., Mansuelle, P., Boudabous, A., Sampieri, F., Sabatier, J.-M., Infect. Disord. Drug Targets, 12, 316-325 (2012).
• Small efficient cell-penetrating peptides derived from scorpion toxin maurocalcine. Poillot, C., Bichraoui, H., Tisseyre, C., Bahembera, E., Andreotti, N., Sabatier, J.-M., Ronjat, M., De Waard, M., J. Biol. Chem., 287, 17331-17342 (2012).
• Strategies toward structural and functional ‘optimization’ of animal peptide toxins. Andreotti, N., Ziadi, H., Mouhat, S., De Waard, M., Sabatier, J.-M., Int. J. Med. Biomed. Res., 1, 91-96 (2012).
• Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Kasamu, A.W., Hougaard, C., Rode, F., Jacobsen, T.A., Sabatier, J.-M., Eriksen, B.L., Strobaek, D., Liang, X., Egorova, P., Vorontsova, D., Christophersen, P., Ronn, L.C., Bezprozvanny, Chemistry & Biology, 19, 1340-1353 (2012).
• Animal venoms: from deadly arsenals (toxins) to therapeutic drug candidates. Sabatier, J.-M., Inflamm. Allergy Drug Targets, 10, 312 (2011). Introduction to a special issue.
• Analysis of the interacting surface of maurotoxin with the voltage-gated Shaker B K+ channel. Fajloun, Z., Andreotti, N., Fathallah, M., Sabatier, J.-M., De Waard, M., J. of Pept. Sci., 17, 200-210 (2011).
• SP receptor blockade decreases stretch-induced lung cytokines and lung injury. Brégeon, F., Steinberg, J.-G., Andreotti, N., Sabatier, J.-M., Delpierre, S., Ravailhe, S., Jammes, Y., J. Physiol., 588, 1309-1319 (2010).
• Protein-protein recognition control by modulating electrostatic interactions. Han, S., Yin, S., Shijin, Y., Mouhat, S., Qiu, S., Cao, Z., Sabatier, J.-M., Wu, Y., Li, W., J. of Proteome Res., 9, 3118-3125 (2010).
• Therapeutic value of peptides from animal venoms. Andreotti, N., Jouirou, B., Mouhat, S., Mouhat, L., Sabatier, J.-M., Amino Acids, Peptides and Proteins, Comprehensive Natural Products II Chemistry and Biology, Mander L. & Lui H.D. Eds., Elsevier: Oxford, vol. 5, pp 287-303, 2010.
• Structure-function relationships of KTS Disintegrins and design of antiangiogenic drugs. Kallech-Ziri, O., Luis, J., Fajloun, Z., Sabatier, J.-M., Lehmann, M., El Ayeb, M., Marrakchi, N., Loret, E., Letters in Drug Design & Discovery, 7, 36-40 (2010).
• Small-conductance Ca2+-activated potassium type 2 channels regulate the formation of contextual fear memory. Nijholt, I., Van den Akker, H., Kye, M.-J., Sabatier, J.-M., Knaus, H., Spiess, J., Blank, T., J. of Neurosci., in press (2009).
• Drug targets in viral infections. Sabatier, J.-M., Infect. Disord. Drug Targets, 9, 100 (2009). Introduction to a special issue.
• Chemical synthesis and 1H-NMR 3D structure determination of AgTx2-MTX chimera, a new potential blocker for Kv1.2 channel, derived from MTX and AgTx2 scorpion toxins. Pimentel, C., M’Barek, S., Visan, V., Grissmer, S., Sampieri, F., Sabatier, J.-M., Darbon, H., Fajloun, Z., Protein Science, 17, 107-118 (2008).
• Animal toxins acting on voltage-gated potassium channels. Mouhat, S., Andreotti, N., Jouirou, B., Sabatier, J.-M., Current Pharmaceutical Design, 14, 2503-2518 (2008).
• Effect of Cu2+ on the oxidative folding of synthetic Maurotoxin in vitro. Regaya, I., Andreotti, N., Di Luccio, E., De Waard, M., Sabatier, J.-M., J. Biomolecular Structure and Dynamics, 26, 75-82 (2008).
• Chemical synthesis and characterization of J46 peptide, an atypical class IIa bacteriocin from Lactococcus lactis subsp. Cremoris J46 strain. Lasta, S., Fajloun, Z., Darbon, H., Mansuelle, P., Andreotti, N., Sabatier, J.-M., Boudabous, A., Sampieri, F., The Journal of Antibiotics, 61, 89-93 (2008).
• Design of a disulfide-less, pharmacologically-inert and chemically-competent analog of Maurocalcine for the efficient transport of impermeant compounds into cells. Ram, N., Weiss, N., Texier-Nogues, I., Aroui, S., Andreotti, N., Pirollet, F., Ronjat, M., Sabatier, J.-M., Darbon, H., Jacquemond, V., De Waard, M., J. Biol. Chem., 283, 27048-27056 (2008).
• Modulators of small and intermediate conductance calcium-activated potassium channels and their therapeutic indications. Wulff, H., Kolski-Andreaco, A., Sankaranayanan, A., Sabatier, J.-M., Shakkottai, V., Current Medicinal Chemistry, 14, 1437-1457 (2007).
• Pharmacological profiling of OSK1 analogues with a trimmed N-terminal domain.Mouhat, S., Teodorescu, G., Homerick, D., Visan, V., Wulff, H., Wu, Y.L., Grissmer, S., Darbon, H., De Waard, M., Sabatier, J.-M., Mol. Pharmacology, 69, 354-362 (2006).
• Cell penetration properties of maurocalcine, a natural venom peptide active on the intracellular ryanodine receptor. Boisseau, S., Mabrouk, K., Narendra, R., Garmy, N., Collin, V., Tadmouri, A., Mikati, M., Sabatier, J.-M., Ronjat, M., Fantini, J., De Waard, M., Biochem. Biophys. Acta, 1758, 308-319 (2006).
• CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity. Guieu, R., Fenouillet, E., Devaux, C., Fajloun, Z., Carrega, L., Sabatier, J.-M., Sauze, N., Marguet, D., Behav. Brain Res., 166, 230-235 (2006).
• Transient loss of voltage control of Ca2+ release in the presence of maurocalcine in skeletal muscle. Pouvreau, S., Csernoch, L., Allard, B., Sabatier, J.-M., De Waard, M., Ronjat, M., Jacquemont, V., Biophys. J., 91, 2206-2215 (2006).
• Resistance of Hepatitis C virus to NS3-4A protease inhibitors: molecular mechanism of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Courcambeck J., Bouzidi, M., Perbost, R., Jouirou, B., Amrani, N., Cacoub, P., Pèpe, J., Sabatier, J.-M., Halfon, P., Antiviral Therapy, 11, 847-855 (2006).
• Block of neural Kv1.1 potassium channels for neuroinflammatory disease therapy. Beraud-Juven, E., Viola, A., Regaya, I., Confort-Gouny, Siaud, P., Ibarrola, D., Le Fur, Y., Barbaria, J., Pélissier, J.-F., Medina, I., Sabatier, J.-M., Cozzone, P., Annals of Neurology, 60, 586-596 (2006).
• K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Mouhat, S., Visan, V., Ananthakrishnan, S., Wulff, H., Grissmer, S., Darbon, H., De Waard, M., Sabatier, J.-M., Biochem. J., 385, 95-104 (2005).
• Contribution of the functional dyad of animal toxins acting on voltage-gated Kv1-type channels. Mouhat, S., De Waard, M., Sabatier, J.-M., J. Peptide Sci., 11, 65-68 (2005).
• Maurocalcine and domain A of the II-III loop of the dihydropyridine receptor Cav1.1 subunit share common binding sites on the skeletal ryanodine receptor. Altafaj, X., Cheng, W., Estève, E., Urbani, J., Grunwald, D., Sabatier, J.-M., Coronado, R., De Waard, M., Ronjat, M., J. Biol. Chem., 280, 4013-4016 (2005).
• Transduction of the scorpion toxin maurocalcine into cells. Evidence that the toxin crosses the plasma membrane. Estève, E., Mabrouk, K., Dupuis, A., Smida-Rezgui, S., Altafaj, X., Grunwald, D., Platel, J.-C., Andreotti, N., Marty, I., M., Sabatier, J.-M., Ronjat, M., De Waard, M., J. Biol. Chem., 280, 12833-12839 (2005).
• Molecular modeling and docking simulations of scorpion toxins and related analogues on human SKCa2 and SKCa3 channels. Andreotti, N., Di Luccio, E., Sampieri, F., De Waard, M., Sabatier, J.-M., Peptides, 26, 1095-1108 (2005). Article ranked first in the « Top 25 Hottest Articles » of Peptides.
• Acting on the number of molecular contacts between Maurotoxin and Kv1.2 channel impacts ligand affinity. M’Barek, S., Chagot, B., Andreotti, N., Visan, V., Mansuelle, P., Grissmer, S., Marrakchi, M., El Ayeb, M., Sampieri, F., Darbon, H., Fajloun, Z., De Waard, M., Sabatier, J.-M., Proteins, 60, 401-411 (2005).
• Differential effects of maurocalcine on Ca2+ release events and depolarisation-induced Ca2+ release in rat skeletal muscle. Szappanos, H., Smida-Rezgui, S., Cseri, J., Simut, C., Sabatier, J.-M., De Waard, M., Kovacs, L., Csernoch, L., Ronjat, M., J. Physiol., 565, 843-853 (2005).
• Blockade of NMDA receptors enhances spontaneous sharp waves in rat hippocampal slices. Colgin, L., Jia, Y., Sabatier, J.-M., Lynch, G., Neuroscience Letters, 385, 46-51 (2005).
• Lebestatin, a short disintegrin from Macrovipera lebetina venom, inhibits integrin-mediated adhesion, migration of tumor cells and in vivo angiogenesis. Kallech-Ziri, O., Luis, J., Daoud, S., Srairi, N., Andreotti, N., Lehmann, M., Zouari, R., Bazaa, A., Marvaldi, J., Sabatier, J.-M., El Ayeb, M., Marrakchi, N., Lab. Invest., 1-10 (2005).
• The impact of the fourth disulfide bridge in scorpion toxins of the -KTx6 sub-family. Carrega, L., Mosbah, A., Ferrat, G., Beeton, C., Andreotti, N., Mansuelle, P., Darbon, H., De Waard, M., Sabatier, J.-M., Proteins, 61, 1010-1023 (2005).
• The « functional » dyad of scorpion toxin Pi1 is not by itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels. Mouhat, S., Mosbah, A., Visan, V., Wulff, H., Delepierre, M., Darbon, H., Grissmer, S., De Waard, M., Sabatier, J.-M., Biochem. J., 377, 25-36 (2004).
• Cobatoxin 1 from Centruroides noxius scorpion venom: Chemical synthesis, 3-D structure in solution, pharmacology and docking on K+ channels. Jouirou, B., Mosbah, A., Visan, V., Grissmer, S., M’Barek, S., Fajloun, Z., Van Rietschoten, J., Devaux, C., Rochat, H., Lippens, G., El Ayeb, M., De Waard, M., Mabrouk, K., Sabatier, J.-M., Biochem. J., 377, 37-49 (2004).
• Diversity of folds in animal toxins acting on ion channels. Mouhat, S., Jouirou, B., Mosbah, A., De Waard, M., Sabatier, J.-M., Biochem. J., 378, 717-726 (2004) ; Impact factor = 29.4.
• Toxin determinants required for interaction with voltage-gated K+ channels. Jouirou, B., Mouhat, S., Andreotti, N., De Waard, M., Sabatier, J.-M., Toxicon, 43, 909-914 (2004).
• Block of maurotoxin and charybdotoxin on human intermediate-conductance calcium-activated potassium channels (hIKCa1). Visan, V., Sabatier, J.-M., Grissmer, S., Toxicon, 43, 973-980 (2004).
• First chemical synthesis of a scorpion -toxin affecting sodium channels : the AaH I toxin of Androctonus australis Hector. M’Barek, S., Fajloun, Z., Cestèle, S., Devaux, C., Mansuelle, P., Mosbah, A., Jouirou, B., Mantegazza, M., Van Rietschoten, J., El Ayeb, M., Rochat, H., Sabatier, J.-M., Sampieri, F., J. Peptide Sci., 10, 666-677 (2004).
• Small conductance calcium-activated K+ channels, SKCa, but not voltage-gated K+ (Kv) channels, are implicated in the antinociception induced by CGS21680, a A2A adenosine receptor agonist. Regaya, I., Pham, T., Andreotti, N., Sauze, N., Carrega, L., Martin-Eauclaire, M.-F., Jouirou, B., Peragut, J.-C, Vacher, H., Rochat, H., Devaux, C., Sabatier, J.-M., Guieu, R., Life Sciences, 76, 367-377 (2004).
• Mapping of maurotoxin (MTX) binding sites on hKv1.2, hKv1.3 and hIKCa1 channels. Visan, V., Fajloun, Z., Sabatier, J.-M., Grissmer, S., Mol. Pharmacology, 66, 1103-1112 (2004).
• Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins. Regaya, I., Beeton, C., Ferrat, G., Andreotti, N., Darbon, H., De Waard, M., Sabatier, J.-M., J. Biol. Chem., 279, 55690-55696 (2004).
• Maurotoxin, a potent inhibitor of intermediate conductance Ca2+-activated potassium channels. Castle, N.A., London, D.B., Creech, C., Fajloun, Z., Stocker, J., Sabatier, J.-M., Mol. Pharmacology, 63, 409-418 (2003).
• Maurocalcine and peptide A stabilize distinct subconductance states of ryanodine receptor type 1 (RyR1) revealing a proportional gating mechanism. Chen, L., Estève, E., Sabatier, J.-M., Ronjat, M., De Waard, M., Allen, P.D., Pessah, I.N., J. Biol. Chem., 278, 16095-16106 (2003).
• Solution structure of Pi4, a short four-disulfide-bridged scorpion toxin specific of potassium channels. Guijarro, J.I., M’Barek, S., Gomez-Lagunas, F., Garnier, D., Rochat, H., Sabatier, J.-M., Possani, L.D., Delepierre, M., Protein Science, 12, 1844-1854 (2003).
• A maurotoxin with constrained standard disulfide bridging – Innovative strategy of chemical synthesis, pharmacology and docking on K+ channels. M’Barek, S., Lopez-Gonzalez, I., Andreotti, N., di Luccio, E., Visan, V., Grissmer, S., Judge, S., El Ayeb, M., Darbon, H., Rochat, H., Sampieri, F., Béraud, E., Fajloun, Z., De Waard, M., Sabatier, J.-M., J. Biol. Chem., 278, 31095-31104 (2003).
• Synthesis and characterization of Pi4, a scorpion toxin from Pandinus imperator that acts on K+ channels. M’Barek, S., Mosbah, A., Sandoz, G., Mansuelle, P., Fajloun, Z., Rochat, H., Sampieri, H., Olamendi-Portugal, T., Possani, L., Delepierre, M., De Waard, M., Sabatier, J.-M., Eur. J. Biochem., 270, 3583-3592 (2003).
• Critical amino acid residues determine the binding affinity and the Ca2+ release efficacy of maurocalcine in skeletal muscle cells. Estève, E., Smida-Rezgui, S., Sarkozi, S., Regaya, I., Chen, L., Altafaj, X., Rochat, H., Allen, P., Pessah, I., Marty, I., Sabatier, J.-M., Jona, I., De Waard, M., Ronjat, M., J. Biol. Chem., 278, 37822-37831 (2003).
• Evolution of Maurotoxin conformation and blocking efficacy towards Shaker B channels during the course of folding and oxidation in vitro. Di Luccio, E., Matavel, A., Opi, S., Regaya, I., Sandoz, G., M’Barek, S., Carlier, E., Estève, E., Carrega, L., Fajloun, Z., Rochat, H., Loret, E., De Waard, M., Sabatier, J.-M., Biochem. J., 361, 409-416 (2002).
• Liposomal encapsulation enhances SPC3 antiviral efficacy against human immunodeficiency virus type 1 infection in human lymphocytes. De Mareuil, J., Mabrouk, K., Doria, E., Moulard, M., De Chasteigner, S., Oughideni, R., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., Antiviral Res., 54, 175-188 (2002).
• The interaction between the I-II loop and the III-IV loop of Cav2.1 contributes to voltage-dependent inactivation in a beta-dependent manner. Geib, S., Sandoz, G., Cornet, V., Mabrouk, K., Fund-Saunier, O., Bichet, D., Villaz, M., Hoshi, T., Sabatier, J.-M., De Waard, M., J. Biol. Chem., 277, 10003-10013 (2002).
• Synthesis, 3-D structure and pharmacology of a reticulated chimera derived from maurotoxin and Tsk scorpion toxins. Fajloun, Z., Ferrat, G., Carlier, E., M’Barek, S., Regaya, I., Fathallah, M., Rochat, H., Darbon, H., De Waard, M., Sabatier, J.-M., Biochem. Biophys. Res. Comm., 291, 640-648 (2002).
• Modeling of the III-IV loop, a domain involved in calcium channel Cav2.1 inactivation, highlights a structural homology with the gamma subunit of G proteins. Fathallah, M., Sandoz, G., Mabrouk, K., Geib, S., Urbani, J., Villaz, M., Ronjat, M., Sabatier, J.-M., De Waard, M., Eur. J. Neuroscience, 16, 219-228 (2002).
• Kaliotoxin, a voltage-gated potassium channel blocker, inhibits encephalitogenic T cell activation. Beeton, C., Barbaria, J., Benoliel, A-M., Giraud, P., Gola, M., Sabatier, J.-M., Bernard, D., Crest, C., Béraud, E., J. Immunol., 166, 936-944 (2001).
• Disulfide bridge reorganization induced by proline mutations in Maurotoxin. Carlier, E., Fajloun, Z., Mansuelle, P., Fathallah, M., Mosbah, A., Oughideni, R., di Luccio, E., Sandoz, G., Geib, S., Regaya, I., Rochat, H., Darbon, H., Sabatier, J.-M., De Waard, M., FEBS Lett., 489, 202-207 (2001).
• Parameters affecting oxidation/folding of Maurotoxin, a four disulfide-bridged scorpion toxin. Di Luccio, E., Azulay, D.O., Regaya, I., Fajloun, Z., Sandoz, G., Mansuelle, P., Kharrat, R., Fathallah, M., Carrega, L., Estève, E., Rochat, H., De Waard, M., Sabatier, J.-M., Biochem. J., 358, 681-692 (2001).
• Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SKCa2. Shakkottai, V., Regaya, I., Wulff, H., Fajloun, Z., Fathallah, M., Tomita, H., Gargus, J.J., Cahalan, M., Sabatier, J.-M., Chandy, K.G., J. Biol. Chem., 276, 43145-43151 (2001).
• Chemical synthesis, molecular modeling and anti-microbial activity of a novel bacteriocin, MMFII. Ferchichi, M., Fathallah, M., Mansuelle, P., Rochat, H., Sabatier, J.-M., Manai, M., Mabrouk, K. Biochem. Biophys. Res. Comm., 289(1), 13-18 (2001).
• Chemical synthesis and characterization of Maurocalcine, a scorpion toxin that activates Ca2+ release channel/ryanodine receptors. Fajloun, Z., Kharrat, R., Chen, L., Lecomte, C., di Luccio, C., Bichet, D., El Ayeb, M., Rochat, H., Allen, P.D., Pessah, I.N., De Waard, M., Sabatier, J.-M., FEBS Lett., 469, 179-185 (2000).
• Maurotoxin and Kv1.1 channel: Voltage-dependent binding upon enantiomerization of the scorpion toxin disulfide bridge Cys 31-Cys 34. Lecomte, C., Ben Khalifa, R., Martin-Eauclaire, M.-F., Kharrat, R., El Ayeb, M., Darbon, H., Rochat, H., Crest, M., Sabatier, J.-M., J. Peptide Res., 55, 246-254 (2000).
• A new fold in the scorpion toxin family, associated with an activity on a ryanodine-sensitive calcium channel. Mosbah, A., Kharrat, R., Fajloun, Z., Renisio, G., Blanc, E., Sabatier, J.-M., El Ayeb, M., Darbon, H., Proteins, 40, 436-442 (2000).
• Synthesis, 1H-NMR structure and activity of a three disulfide-bridged Maurotoxin analog designed to restore the consensus motif of scorpion toxins. Fajloun, Z., Ferrat, G., Carlier, C., Fathallah, M., Lecomte, C., Sandoz, G., di Luccio, E., Mabrouk, K., Legros, C., Darbon, H., Rochat, H., Sabatier, J.-M., De Waard, M., J. Biol. Chem., 275, 13605-13612 (2000).
• Maurotoxin, a four disulfide-bridged toxin from the chactoid scorpion Scorpio maurus, blocks voltage-gated K+ channels. Carlier, E., Avdonin, V., Geib, S., Kharrat, R., Rochat, H., Sabatier, J.-M., Hoshi, T., De Waard, M., J. Peptide Res., 55, 419-427 (2000).
• Biophysical and molecular mechanisms of the action of Maurotoxin on Shaker potassium channels. Avdonin, V., Nolan, B., Sabatier, J.-M., De Waard, M., Hoshi, T., Biophys. J., 79, 776-787 (2000).
• Chemical synthesis and characterization of Pi1, a scorpion toxin from Pandinus imperator active on K+ channels. Fajloun, Z., Carlier, E., Lecomte, C., Geib, S., di Luccio, E., Bichet, D., Mabrouk, K., Rochat, H., De Waard, M., Sabatier, J.-M., Eur. J. Biochem., 267, 5149-5155 (2000).
• Reversibility of the Ca 2+ channel alpha1-beta subunit interaction. Bichet, D., Lecomte, C., Sabatier, J.-M., Felix, R., De Waard, M., Biochem. Biophys. Res. Com., 277, 729-735 (2000).
• Maurotoxin vs Pi1/HsTx1: Towards new insights in the understanding of their distinct disulfide bridge patterns. Fajloun, Z., Mosbah, A., Carlier, E., Mansuelle, P., Fathallah, M., Sandoz, G., di Luccio, E., Devaux, C., Rochat, H., Darbon, H., De Waard, M., Sabatier, J.-M., J. Biol. Chem., 275, 39394-39402 (2000).
• Ion channel activation by SPC3, a peptide derived from the HIV-1 gp120 V3 loop. Carlier, C., Mabrouk, K., Moulard, M., Rochat, H., De Waard, M., Sabatier, J.-M., J. Peptide Res., 56, 427-437 (2000).
• Chemical synthesis and structure-activity of TsK, a novel scorpion toxin acting on apamin-sensitive SK channel. Lecomte, C., Ferrat, G., Fajloun, Z., Van Rietschoten, J., Rochat, H., Martin-Eauclaire, M.-F., Darbon, H., Sabatier, J.-M., J. Peptide Res., 54, 369-376 (1999).
• V3 loop-derived peptide SPC3 inhibits infection of CD4-negative and Galactosylceramide-negative cells by LAV-2/B. Moulard, M., Mabrouk, K., Martin, I., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., J. Peptide Res., 53, 647-655 (1999).
• Three-dimensional structure of scorpion toxins: Towards a new model of interaction with potassium channels. Darbon, H., Blanc, E., Sabatier, J.-M., Perspectives in Drug Discovery and Design, H. Darbon & J.-M. Sabatier Eds., KLUWER/ESCOM, Kluwer Academic Publishers 15/16, 40-60 (1999).
• An anti-HIV peptide construct derived from the cleavage region of the Env precursor acts on Env fusogenicity through the presence of a functional cleavage sequence. Barbouche, R., Sabatier, J.-M., Fenouillet, E., Virology, 247, 137-143 (1998).
• Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials. Barbouche, R., Fenouillet, E., Papandréou, M.-J., Kiény, M.-P., Sabatier, J.-M., J. Peptide Res., 52, 283-288 (1998).
• Synthetic peptides as tools to investigate the structure and pharmacology of potassium channel-acting short-chain scorpion toxins. Lecomte, C., Sabatier, J.-M., Van Rietschoten, J., Rochat, H., Biochimie, 80, 151-154 (1998).
• Maurotoxin, a four disulfide bridges scorpion toxin acting on K+ channels. Rochat, H., Kharrat, R., Sabatier, J.-M., Mansuelle, P., Crest, M., Martin-Eauclaire, M.-F., Sampieri, F., Oughideni, R., Mabrouk, K., Jacquet, G., Van Rietschoten, J., El Ayeb, M., Toxicon, 36, 1609-1611 (1998).
• SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells. Barbouche, R., Miquelis, R., Sabatier, J.-M., Fenouillet, E., J. Peptide Science, 4, 479-485 (1998).
• In vivo protection against Androctonus australis Hector scorpion toxin and venom by immunization with a synthetic analog of toxin II. Zenouaki, I., Kharrat, R., Sabatier, J.-M., Devaux, C., Karaoui, H., Van Rietschoten, J., El Ayeb, M., Rochat, H., Vaccine, 15, 187-194 (1997).
• Monoclonal antibodies neutralizing the toxin II from Androctonus australis Hector scorpion venom: usefulness of a synthetic, non-toxic analog. Devaux, C., Clot-Faybesse, O., Juin, M., Mabrouk, K., Sabatier, J.-M., Rochat, H., FEBS, 412,456-460 (1997).
• Differential involvement of disulfide bridges on the folding of a scorpion toxin. Calabro, V., Sabatier, J.-M., Blanc, E., Lecomte, C., Van Rietschoten, J., Darbon, H., J. Peptide Res., 50, 39-47 (1997).
• Solution structure of Maurotoxin, a scorpion toxin from Scorpio maurus, with high affinity for voltage-gated potassium channels. Blanc, E., Sabatier, J.-M., Kharrat, R., Meunier, S., El Ayeb, M., Van Rietschoten, J., Darbon, H., Proteins, 29, 321-333 (1997).
• Solution structure of TsKapa, a charybdotoxin-like scorpion toxin from Tityus serrulatus with high affinity for apamin-sensitive Ca2+-activated K+ channels. Blanc, E., Lecomte, C., Van Rietschoten, J., Sabatier, J.-M., Darbon, H., Proteins, 29, 359-369 (1997).
• V3 loop-derived multibranched peptides as inhibitors of HIV infection in CD4+ and CD4- cells. Fantini, J., Yahi, N., Mabrouk, K., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., Perspectives in Drug Discovery and Design, J. Fantini & J.-M. Sabatier Eds., Escom Science Publishers, 5, 243-250 (1996).
• Chemical synthesis and characterization of Maurotoxin, a short scorpion toxin with four disulfide bridges acting on K+ channels. Kharrat, R., Mabrouk, K., Crest, M., Darbon, H., Oughideni, R., Martin-Eauclaire, M.-F., Jacquet, G., El Ayeb, M., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., Eur. J. Biochem., 242, 491-498 (1996).
• Synthesis and characterization of Leiurotoxin I analogs lacking one disulfide bridge: Evidence that disulfide pairing 3-21 is not required for full toxin activity. Sabatier, J.-M., Lecomte, C., Mabrouk, K., Darbon, H., Oughideni, R., Canarelli, S., Rochat, H., Martin-Eauclaire, M.-F., Van Rietschoten, J., Biochemistry, 35, 10641-10647 (1996).
• Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope. Sabatier, J.-M., Mabrouk, K., Moulard, M., Rochat, H., Van Rietschoten, J., Fenouillet, E., Virology, 223, 406-408 (1996).
• Structure-activity relationship study of a scorpion toxin with high affinity for apamin-sensitive potassium channels by means of the solution structure of analogues. Inisan, A.G., Meunier, S., Fedelli, O., Altbach, M., Fremont, V., Sabatier, J.-M., Thévan, A., Cambillau, C., Darbon, H., Int. J. Peptide Protein Res., 45, 441-450 (1995).
• Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of HIV-1 gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line. Yahi, N., Sabatier, J.-M., Baghdiguian, S., Gonzalez-Scarano, F., Fantini, J., J. Virol., 69, 320-325 (1995).
• SPC3, a nontoxic peptide inhibitor of HIV infection. Sabatier, J.-M., Baghdiguian, S., Yahi, N., Rochat, H., Van Rietschoten, J., Fantini, J., In Vitro, 31, 415-418 (1995).
• SPC3, a synthetic peptide derived from the V3 domain of HIV-1 gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms. Yahi, N., Fantini, J., Baghdiguian, S., Mabrouk, K., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., Proc. Natl. Acad. Sci. USA, 92, 4867-4871 (1995).
• Rôle des glycolipides dans l'infection des cellules par le virus du SIDA. Fantini, J., Baghdiguian, S., Sabatier, J.-M., Yahi, N., Journal Français des Oléagineux, Acides gras et Lipides, 2, 104-107 (1995).
• Structural and pharmacological diversity of scorpion neurotoxins. Darbon, H., Sabatier, J.-M., Current Topics in Peptide Protein Res., 1, (1994).
• Des constructions peptidiques (SPC) inhibent l'entrée du VIH dans les cellules: Une nouvelle classe d'anti-rétroviraux. Fantini, J., Yahi, N., Mabrouk, K., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., Science, Technique et Technologie, N° 26, 4-8 (1994).
• Leiurotoxin I, a scorpion toxin specific for Ca2+- activated K+ channels: Structure-activity analysis using synthetic analogs. Sabatier, J.-M., Fremont, V., Mabrouk, K., Crest, M., Darbon, H., Rochat, H., Van Rietschoten, J., Martin-Eauclaire, M.-F., Int. J. Peptide Protein Res., 43, 486-495 (1994).
• Evaluation of multi-branched peptides as inhibitors of HIV infection. Yahi, N., Fantini, J., Mabrouk, K., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., Letters in Peptide Science, 1, 17-24 (1994).
• Multi-branched peptide constructs (MBPC) of the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus-induced syncytium formation. Benjouad, A., Fenouillet, E., Gluckman, J.-C., Sabatier, J.-M., Antiviral Chemistry and Chemotherapy, 5, 195-196 (1994).
• Multi-branched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages. Yahi, N., Fantini, J., Mabrouk, K., Tamalet, C., De Micco, P., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., J. Virol., 68, 5714-5720 (1994).
• Suramin inhibits binding of the V3 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 to galactosyl ceramide (GalCer). Yahi, N., Sabatier, J.-M., Nickel, P., Mabrouk, K., Gonzalez-Scarano, F., Fantini, J., J. Biol. Chem., 269, 24349-24353 (1994).
• Multi-branched V3 peptides as HIV inhibitors. Fantini, J., Yahi, N., Mabrouk, K., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., Current Topics in Peptide Protein Res., 1, 11-24 (1994).
• Multi-branched peptides based on the HIV-1 V3 loop consensus motif inhibit HIV-1 and HIV-2 infection in CD4+ and CD4- cells. Fantini, J., Yahi, N., Mabrouk, K., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., C. R. Acad. Sci., 316, 1381-1387 (1993).
• Solution structure of P05-NH2, a scorpion toxin analog with high affinity for apamin-sensitive potassium channel. Meunier, S., Bernassau, J.-M., Sabatier, J.-M., Martin-Eauclaire, M.-F., Van Rietschoten, J., Cambillau, C., Darbon, H., Biochemistry, 32, 11969-11976 (1993).
• P05, a new leiurotoxin I scorpion toxin: synthesis and structure-activity relationships of the -amidated analog, a ligand of Ca2+- activated K+ channels with increased affinity. Sabatier, J.-M., Zerrouk, H., Darbon, H., Mabrouk, K., Benslimane, A., Rochat, H., Martin-Eauclaire, M.-F., Van Rietschoten, J., Biochemistry, 32, 2763-2770 (1993).
• Characterization of minor and major antigenic regions within the hepatitis B virus nucleocapsid (HBcAg). Tordjman, M., Fontan, G., Rabillon, V., Martin, J., Trepo, C., Hoffenbach, A., Mabrouk, K., Sabatier, J.-M., Van Rietschoten, J., Somme, G., J. Med.Virol., 41, 3221-3229 (1993).
• Cytotoxic effect on lymphocytes of Tat from human immunodeficiency virus type 1. Benjouad, A., Mabrouk, K., Moulard, M., Gluckman, J.-C., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., FEBS, 319, 119-124 (1993).
• La protéine Nef du virus HIV-1 : facteur de controverse. Sabatier, J.-M., Van Rietschoten, J., Granier, C., Bahraoui, E., Médecine/Sciences, 7, 62-65 (1991).
• Evidence for neurotoxic activity of Tat from human immunodeficiency virus type 1. Sabatier, J.-M., Vives, E., Mabrouk, K., Benjouad, A., Rochat, H., Duval, A., Hue, B., Bahraoui, E., J. Virol., 65, 961-967 (1991).
• Lethal neurotoxicity in mice of the basic domains of HIV and SIV Rev proteins: Study of these regions by circular dichroism. Mabrouk, K., Van Rietschoten, J., Vives, E., Darbon, H., Rochat, H., Sabatier, J.-M., FEBS, 289, 13-17 (1991).
• Large fragments of Nef-protein and gp110 envelope glycoprotein from HIV-1 : synthesis, CD analysis and immunoreactivity. Sabatier, J.-M., Fontan, G., Loret, E., Mabrouk, K., Rochat, H., Gluckman, J.-C., Montagnier, L., Granier, C., Bahraoui, E., Van Rietschoten, J., Int. J. Peptide Protein Res. , 35, 63-72 (1990).
• Immunogenicity and antigenicity of the human immunodeficiency virus (HIV) recombinant nef gene product. Mapping of T- and B-cell epitopes in immunized chimpanzees. Bahraoui, E., Yagello, M., Billaud, J.-N., Sabatier, J.-M., Guy, B., Muchmore, E., Girard, M., Gluckman, J.-C., AIDS Res. Hum. Retrovir., 6, 1087-1098 (1990).
• Relevance of anti-Nef antibodies detection as an early serological marker of HIV infection. Bahraoui, E., Benjouad, A., Sabatier, J.-M., Allain, J.-P., Laurian, Y., Montagnier, L., Gluckman, J.-C., Blood, 76, 257-264 (1990).
• Identification of a common domain in calmodulin-activated eukaryotic and bacterial adenylate cyclases. Goyard, S., Orlando, C., Sabatier, J.-M., Labruyère, E., D'Alayer, J., Fontan G., Van Rietschoten, J., Mock, M., Danchin, A., Ullmann, A., Monneron, A., Biochemistry, 28, 1964-1967 (1989).
• Convergent solid phase peptide synthesis VII. Good yields in the coupling of protected segments on a solid support. Grandas, A., Albericio, F., Pedroso, E., Giralt, E., Sabatier, J.-M., Van Rietschoten, J., Tetrahedron, 45, 4637-4648 (1989).
• Use of synthetic peptides for the detection of antibodies against the Nef regulating protein in sera of HIV-infected patients. Sabatier, J.-M., Clerget, B., Fontan, G., Fenouillet, E., Granier, C., Gluckman, J.-C., Rochat, H., Van Rietschoten, J., Montagnier, L., Bahraoui, E., AIDS, 3, 215-220 (1989).
• Accessibility of the highly conserved amino- and carboxy- terminal regions from HIV-1 external envelope glycoprotein. Bahraoui, E., Clerget, B., Granier, C., Van Rietschoten, J., Sabatier, J.-M., Rochat, H., Gluckman, J.-C., Montagnier, L., AIDS Res. Hum. Retrovir., 5, 451-463 (1989).
• Convergent solid phase peptide synthesis: recent progresses. Van Rietschoten, J., Sabatier, J.-M., Tessier, M., Granier, C., Pedroso, E., Grandas, A., Albericio, F., Eritja, R., Nicolas, E., Josa, J., Giralt, E., Protides of the Biological Fluids, H. Peeters Ed., Pergamon Press, 1987, pp. 23-26.
• Reduction and reoxidation of the neurotoxin II from the scorpion Androctonus australis Hector. Sabatier, J.-M., Darbon, H., Fourquet, P., Rochat, H., Van Rietschoten, J., Int. J. Peptide Protein Res., 30, 125-134 (1987).
• Convergent solid phase peptide synthesis VI: Syntheses by the Fmoc-amino acids with a modified protocol of two protected segments ; sequence 5-17 and 18-31 of the neurotoxin II of the scorpion Androctonus australis Hector. Sabatier, J.-M., Tessier-Rochat, M., Granier, C., Van Rietschoten, J., Pedroso, E., Grandas, A., Albericio, F., Giralt, E., Tetrahedron, 43, 5973-5980 (1987).
• A specific immunological probe for the major myelin proteolipid; confirmation of a deletion in DM 20. Trifilieff, E., Luu, B., Nussbaum, J.-L., Espinosa de los Monteros, A., Sabatier, J.-M., Van Rietschoten, J., FEBS, 198, 235-239 (1986).

• Section Editor for book sections on venom peptides: «Handbook of Biologically-Active Peptides». 1st and 2nd Editions, Elsevier Publishers (2006 & 2012).
• Editor of a book «Animal Toxins and Potassium Channels». Perspectives in Drug Discovery and Design, Vols. 15/16, Kluwer Academic Publishers (1999).
• Editor of a book «HIV Infection in CD4- cells». Perspectives in Drug Discovery and design, Vol. 5, Escom Science Publishers (1996).
• Animal Toxins in the World of Modern Biotechnologies. Sabatier, J.-M., De Waard, M., « Handbook of Biologically-Active Peptides», 2nd Edition, Kastin A. Ed., Elsevier Publishers (2012).
• Structure-Function Strategies to Improve the Pharmacological Value of Animal Toxins. De Waard, M., Sabatier, J.-M., «Handbook of Biologically-Active Peptides», Kastin A. Ed., Elsevier Publishers (2006).
• Methodological Approaches to the Study of Ion Channels using Peptide Toxins: Proposed Comprehensive Guidelines. De Waard, M., Sabatier, J.-M., Rochat, H., «Perspectives in Molecular Toxinology», Ménez A. Ed., John Wiley & Sons Ltd., pp 255-269 (2002).
• Chemical Synthesis and Characterization of Small Proteins: Example of Scorpion Toxins. Sabatier, J.-M., Handbook of Toxinology, "Animal Toxins: Tools in Cell Biology", Chapman & Hall, Birkhäuser Verlag Basel/Switzerland, pp 196-216 (2000).

• https://orcid.org/0000-0002-9040-5647
• https://www.scopus.com/authid/detail.uri?authorId=7102018305
• https://sciprofiles.com/profile/11509
• https://loop.frontiersin.org/people/778429